{"name":"Bristol-Myers Squibb Co.","slug":"bristol-myers-squibb","ticker":"BMY","exchange":"NYSE","domain":"bms.com","description":"Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-","hq":"Princeton, NJ","founded":0,"employees":"32500","ceo":"Christopher Boerner","sector":"Big Pharma","stockPrice":56.65,"stockChange":0.26,"stockChangePercent":0.46,"marketCap":"$115.7B","metrics":{"revenue":48194000000,"revenueGrowth":2.6,"grossMargin":72,"rdSpend":9951000000,"netIncome":7054000000,"cash":10209000000,"dividendYield":4.47,"peRatio":15.9,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","revenue":14443000000,"yoyGrowth":0,"percentOfTotal":34},{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","revenue":9200000000,"yoyGrowth":0,"percentOfTotal":21.6},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","revenue":5809000000,"yoyGrowth":0,"percentOfTotal":13.7},{"name":"Orencia","genericName":"abatacept","slug":"abatacept","revenue":3705000000,"yoyGrowth":0,"percentOfTotal":8.7},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","revenue":2900000000,"yoyGrowth":0,"percentOfTotal":6.8},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":6.6},{"name":"Breyanzi","genericName":"LISOCABTAGENE MARALEUCEL","slug":"lisocabtagene-maraleucel","revenue":1358000000,"yoyGrowth":0,"percentOfTotal":3.2},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","revenue":800000000,"yoyGrowth":0,"percentOfTotal":1.9},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","revenue":600000000,"yoyGrowth":0,"percentOfTotal":1.4},{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","revenue":427000000,"yoyGrowth":0,"percentOfTotal":1},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","revenue":291000000,"yoyGrowth":0,"percentOfTotal":0.7},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","revenue":205000000,"yoyGrowth":0,"percentOfTotal":0.5}],"timeline":[{"date":"1945-01-01","label":"Dextrotubocurarine Chloride first approved","drug":"Dextrotubocurarine Chloride","drugSlug":"tubocurarine","type":"approval","sentiment":"positive"},{"date":"1963-01-01","label":"Acetadote first approved","drug":"Acetadote","drugSlug":"acetylcysteine","type":"approval","sentiment":"positive"},{"date":"1965-01-01","label":"Unasyn first approved","drug":"Unasyn","drugSlug":"ampicillin","type":"approval","sentiment":"positive"},{"date":"1967-01-01","label":"Moditen Enanthate first approved","drug":"Moditen Enanthate","drugSlug":"fluphenazine-enanthate","type":"approval","sentiment":"positive"},{"date":"1971-01-01","label":"Megace first approved","drug":"Megace","drugSlug":"megestrol-acetate","type":"approval","sentiment":"positive"},{"date":"1972-01-01","label":"Prolixin Decanoate first approved","drug":"Prolixin Decanoate","drugSlug":"fluphenazine-decanoate","type":"approval","sentiment":"positive"},{"date":"1973-01-01","label":"Kanacin first approved","drug":"Kanacin","drugSlug":"kanamycin","type":"approval","sentiment":"positive"},{"date":"1973-01-01","label":"Blenoxane first approved","drug":"Blenoxane","drugSlug":"bleomycin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cefaprin first approved","drug":"Cefaprin","drugSlug":"cefapirin","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Cefradex first approved","drug":"Cefradex","drugSlug":"cefradine","type":"approval","sentiment":"positive"},{"date":"1975-01-01","label":"Delalutin first approved","drug":"Delalutin","drugSlug":"hydroxyprogesterone-caproate","type":"approval","sentiment":"positive"},{"date":"1981-01-01","label":"Arikayce Kit first approved","drug":"Arikayce Kit","drugSlug":"amikacin","type":"approval","sentiment":"positive"},{"date":"1983-01-01","label":"Vepesid first approved","drug":"Vepesid","drugSlug":"etoposide","type":"approval","sentiment":"positive"},{"date":"1986-01-01","label":"Azactam first approved","drug":"Azactam","drugSlug":"aztreonam","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Videx first approved","drug":"Videx","drugSlug":"didanosine","type":"approval","sentiment":"positive"},{"date":"1994-01-01","label":"Serzone first approved","drug":"Serzone","drugSlug":"nefazodone","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Sustiva first approved","drug":"Sustiva","drugSlug":"efavirenz","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Thalomid first approved","drug":"Thalomid","drugSlug":"thalidomide","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Reyataz first approved","drug":"Reyataz","drugSlug":"atazanavir","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Vidaza first approved","drug":"Vidaza","drugSlug":"azacitidine","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Revlimid first approved","drug":"Revlimid","drugSlug":"lenalidomide","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Orencia first approved","drug":"Orencia","drugSlug":"abatacept","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Baraclude first approved","drug":"Baraclude","drugSlug":"entecavir","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Yervoy first approved","drug":"Yervoy","drugSlug":"ipilimumab","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Nulojix first approved","drug":"Nulojix","drugSlug":"belatacept","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Eliquis first approved","drug":"Eliquis","drugSlug":"apixaban","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Pomalyst first approved","drug":"Pomalyst","drugSlug":"pomalidomide","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Opdivo first approved","drug":"Opdivo","drugSlug":"nivolumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Huluc63 first approved","drug":"Huluc63","drugSlug":"elotuzumab","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Daklinza first approved","drug":"Daklinza","drugSlug":"daclatasvir","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Idhifa first approved","drug":"Idhifa","drugSlug":"enasidenib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Inrebic first approved","drug":"Inrebic","drugSlug":"fedratinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Inrebic first approved","drug":"Inrebic","drugSlug":"fedratinib-hydrochloride","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Zeposia first approved","drug":"Zeposia","drugSlug":"ozanimod","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Camzyos first approved","drug":"Camzyos","drugSlug":"mavacamten","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Sotyktu first approved","drug":"Sotyktu","drugSlug":"deucravacitinib","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Krazati first approved","drug":"Krazati","drugSlug":"adagrasib","type":"approval","sentiment":"positive"},{"date":"2026-05-21","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"Krazati PHASE1,PHASE2 readout","drug":"Krazati","drugSlug":"adagrasib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-12-31","label":"REZIPAS Phase 3 readout (Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis)","drug":"REZIPAS","drugSlug":"aminosalicylic-acid-resin-complex","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-16","label":"OPDUALAG Phase 3 readout (Advanced Melanoma)","drug":"OPDUALAG","drugSlug":"relatlimab-rmbw","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-18","label":"OPDUALAG Phase 3 readout (Melanoma)","drug":"OPDUALAG","drugSlug":"relatlimab-rmbw","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-07-20","label":"REZIPAS Phase 2 readout (Inflammatory Bowel Diseases)","drug":"REZIPAS","drugSlug":"aminosalicylic-acid-resin-complex","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-05-14","label":"Vidaza patent expiry (Method of Use)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2029-05-14","label":"Vidaza patent expiry (Formulation)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-03","label":"Vidaza patent expiry (Formulation)","drug":"Vidaza","drugSlug":"azacitidine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-12-31","label":"REZIPAS Phase 2 readout (Ulcerative Colitis, Fecal Microbiota Transplantation)","drug":"REZIPAS","drugSlug":"aminosalicylic-acid-resin-complex","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-02-24","label":"Eliquis patent expiry (Formulation)","drug":"Eliquis","drugSlug":"apixaban","type":"patent_expiry","sentiment":"negative"},{"date":"2031-07-21","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2031-08-24","label":"Eliquis patent expiry (Compound)","drug":"Eliquis","drugSlug":"apixaban","type":"patent_expiry","sentiment":"negative"},{"date":"2031-10-01","label":"OPDUALAG Phase 3 readout (Melanoma, Cutaneous Malignant)","drug":"OPDUALAG","drugSlug":"relatlimab-rmbw","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-04-06","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Method of Use)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2032-05-08","label":"Acetadote patent expiry (Formulation)","drug":"Acetadote","drugSlug":"acetylcysteine","type":"patent_expiry","sentiment":"negative"},{"date":"2033-07-10","label":"OPDUALAG Phase 3 readout (Melanoma)","drug":"OPDUALAG","drugSlug":"relatlimab-rmbw","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-01-31","label":"OPDIVO QVANTIG Phase 3 readout (Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma)","drug":"OPDIVO QVANTIG","drugSlug":"hyaluronidase-nvhy","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-08-31","label":"OPDUALAG Phase 3 readout (Advanced Melanoma)","drug":"OPDUALAG","drugSlug":"relatlimab-rmbw","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Orencia patent cliff ($2.5B at risk)","drug":"Orencia","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Yervoy patent cliff ($1.5B at risk)","drug":"Yervoy","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":20914000000,"percentOfTotal":49.2,"drugCount":39,"colorKey":"immunology","drugs":[{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","indication":"Advanced melanoma with tumour cell PD-L1 expression below 1%","status":"marketed","revenue":9200000000},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","indication":"Follicular lymphoma","status":"marketed","revenue":5809000000},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","indication":"High grade squamous intraepithelial neoplasia of esophagus","status":"discontinued","revenue":2900000000},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","indication":"Multiple myeloma","status":"marketed","revenue":2800000000},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","indication":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","status":"marketed","revenue":205000000},{"name":"Huluc63","genericName":"elotuzumab","slug":"elotuzumab","indication":"Multiple myeloma","status":"marketed"},{"name":"Vidaza","genericName":"azacitidine","slug":"azacitidine","indication":"Refractory Anemia (RA)","status":"marketed"},{"name":"Vepesid","genericName":"etoposide","slug":"etoposide","indication":"Malignant tumor of testis","status":"marketed"},{"name":"BMS-986231","genericName":"BMS-986231","slug":"bms-986231","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BMS-986374","genericName":"BMS-986374","slug":"bms-986374","indication":"Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion","status":"marketed"},{"name":"Blenoxane","genericName":"BLEOMYCIN","slug":"bleomycin","indication":"Diffuse non-Hodgkin's lymphoma, large cell","status":"marketed"},{"name":"Cetuximab/Erbitux","genericName":"Cetuximab/Erbitux","slug":"cetuximab-erbitux","indication":"Metastatic colorectal cancer (KRAS wild-type)","status":"phase_3"},{"name":"Idhifa","genericName":"ENASIDENIB","slug":"enasidenib","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Immunotherapy monotherapy","genericName":"Immunotherapy monotherapy","slug":"immunotherapy-monotherapy","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"OPDUALAG","genericName":"RELATLIMAB-RMBW","slug":"relatlimab-rmbw","indication":"Advanced melanoma with tumour cell PD-L1 expression below 1%","status":"marketed"},{"name":"ABA, open-label (OL)","genericName":"ABA, open-label (OL)","slug":"aba-open-label-ol","indication":"Metastatic melanoma","status":"phase_3"},{"name":"BET Inhibitor","genericName":"BET Inhibitor","slug":"bet-inhibitor","indication":"T-cell lymphoma","status":"phase_2"},{"name":"BMS-650032","genericName":"BMS-650032","slug":"bms-650032","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-790052","genericName":"BMS-790052","slug":"bms-790052","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-936558 (Nivolumab)","genericName":"BMS-936558 (Nivolumab)","slug":"bms-936558-nivolumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"BMS-954561","genericName":"BMS-954561","slug":"bms-954561","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"BMS-986165 Dose A","genericName":"BMS-986165 Dose A","slug":"bms-986165-dose-a","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-986165 Dose B","genericName":"BMS-986165 Dose B","slug":"bms-986165-dose-b","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"BMS-986177","genericName":"BMS-986177","slug":"bms-986177","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"BMS-986504","genericName":"BMS-986504","slug":"bms-986504","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"Carboplatin/Paraplatin","genericName":"Carboplatin/Paraplatin","slug":"carboplatin-paraplatin","indication":"Ovarian cancer","status":"phase_3"},{"name":"Cisplatin/Platinol","genericName":"Cisplatin/Platinol","slug":"cisplatin-platinol","indication":"Metastatic testicular cancer","status":"phase_3"},{"name":"Corticosteroid: Meprednisone","genericName":"Corticosteroid: Meprednisone","slug":"corticosteroid-meprednisone","indication":"Treatment of various cancers","status":"phase_2"},{"name":"Fluorouracil/Adrucil","genericName":"Fluorouracil/Adrucil","slug":"fluorouracil-adrucil","indication":"Colorectal cancer","status":"phase_3"},{"name":"Megace","genericName":"MEGESTROL ACETATE","slug":"megestrol-acetate","indication":"Anorexia from HIV","status":"marketed"},{"name":"NKTR-214","genericName":"NKTR-214","slug":"nktr-214","indication":"Metastatic melanoma (in combination with nivolumab)","status":"phase_3"},{"name":"Nivolumab and rHuPH20","genericName":"Nivolumab and rHuPH20","slug":"nivolumab-and-rhuph20","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Nivolumab in combination with Ipilimumab","genericName":"Nivolumab in combination with Ipilimumab","slug":"nivolumab-in-combination-with-ipilimumab","indication":"Metastatic melanoma","status":"marketed"},{"name":"Nivolumab-relatlimab FDC","genericName":"Nivolumab-relatlimab FDC","slug":"nivolumab-relatlimab-fdc","indication":"Melanoma (advanced or metastatic)","status":"phase_3"},{"name":"Nivolumab/rHuPH20","genericName":"Nivolumab/rHuPH20","slug":"nivolumab-rhuph20","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Placebo for Ipilimumab","genericName":"Placebo for Ipilimumab","slug":"placebo-for-ipilimumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"SAR302503","genericName":"SAR302503","slug":"sar302503","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Thalomid","genericName":"THALIDOMIDE","slug":"thalidomide","indication":"Newly Diagnosed Multiple Myeloma","status":"marketed"},{"name":"Yervoy","genericName":"Yervoy","slug":"yervoy","indication":"High grade squamous intraepithelial neoplasia of esophagus","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":15043000000,"percentOfTotal":35.4,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","indication":"Arterial embolus and thrombosis","status":"marketed","revenue":14443000000},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","indication":"Obstructive hypertrophic cardiomyopathy (HCM)","status":"marketed","revenue":600000000},{"name":"BMS-986278","genericName":"BMS-986278","slug":"bms-986278","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"Ramipril + Irbesartan","genericName":"Ramipril + Irbesartan","slug":"ramipril-irbesartan","indication":"Hypertension in patients not adequately controlled on monotherapy","status":"marketed"},{"name":"BMS-986205","genericName":"BMS-986205","slug":"bms-986205","indication":"Acute coronary syndrome","status":"phase_3"},{"name":"HCTZ monotherapy","genericName":"HCTZ monotherapy","slug":"hctz-monotherapy","indication":"Hypertension","status":"phase_3"},{"name":"Inrebic","genericName":"FEDRATINIB","slug":"fedratinib","indication":"Myelofibrosis","status":"marketed"},{"name":"Approved Hypertrophic Cardiomyopathy drug treatments","genericName":"Approved Hypertrophic Cardiomyopathy drug treatments","slug":"approved-hypertrophic-cardiomyopathy-drug-treatments","indication":"Hypertrophic cardiomyopathy","status":"phase_2"},{"name":"Inrebic","genericName":"FEDRATINIB HYDROCHLORIDE","slug":"fedratinib-hydrochloride","indication":"Myelofibrosis","status":"marketed"},{"name":"Irbesartan monotherapy","genericName":"Irbesartan monotherapy","slug":"irbesartan-monotherapy","indication":"Hypertension","status":"phase_3"},{"name":"Irbesartan/HCTZ","genericName":"Irbesartan/HCTZ","slug":"irbesartan-hctz","indication":"Hypertension (high blood pressure)","status":"phase_3"},{"name":"Nitroglycerin (NTG)","genericName":"Nitroglycerin (NTG)","slug":"nitroglycerin-ntg","indication":"Acute angina pectoris (sublingual/spray formulation)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":4796000000,"percentOfTotal":11.3,"drugCount":25,"colorKey":"cardiovascular","drugs":[{"name":"Orencia","genericName":"abatacept","slug":"abatacept","indication":"Juvenile idiopathic arthritis","status":"marketed","revenue":3705000000},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","indication":"Multiple sclerosis","status":"marketed","revenue":800000000},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","indication":"Moderate-to-severe plaque psoriasis","status":"marketed","revenue":291000000},{"name":"BMS-986165","genericName":"BMS-986165","slug":"bms-986165","indication":"Psoriasis","status":"marketed"},{"name":"Abatacept subcutaneous","genericName":"Abatacept subcutaneous","slug":"abatacept-subcutaneous","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Anti-IL8","genericName":"Anti-IL8","slug":"anti-il8","indication":"Moderate to severe chronic plaque psoriasis","status":"phase_2"},{"name":"Anti-IP-10 Antibody","genericName":"Anti-IP-10 Antibody","slug":"anti-ip-10-antibody","indication":"Psoriasis","status":"phase_2"},{"name":"Any biologic treatment for psoriasis","genericName":"Any biologic treatment for psoriasis","slug":"any-biologic-treatment-for-psoriasis","indication":"Moderate to severe plaque psoriasis","status":"phase_2"},{"name":"Corticosteroid: Methylprednisolone","genericName":"Corticosteroid: Methylprednisolone","slug":"corticosteroid-methylprednisolone","indication":"Multiple sclerosis","status":"phase_2"},{"name":"Corticosteroid: Prednisone","genericName":"Corticosteroid: Prednisone","slug":"corticosteroid-prednisone","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Double-blind Abatacept","genericName":"Double-blind Abatacept","slug":"double-blind-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Infliximab (INF) + MTX, DB","genericName":"Infliximab (INF) + MTX, DB","slug":"infliximab-inf-mtx-db","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Intravenous (IV) abatacept","genericName":"Intravenous (IV) abatacept","slug":"intravenous-iv-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Open-label Abatacept","genericName":"Open-label Abatacept","slug":"open-label-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Orencia","genericName":"Orencia","slug":"orencia","indication":"Juvenile idiopathic arthritis","status":"marketed"},{"name":"PLA + MTX switched to ABA+ MTX, DB","genericName":"PLA + MTX switched to ABA+ MTX, DB","slug":"pla-mtx-switched-to-aba-mtx-db","indication":"Rheumatoid arthritis (as part of combination therapy with MTX)","status":"phase_3"},{"name":"Placebo (PLA) + MTX, DB","genericName":"Placebo (PLA) + MTX, DB","slug":"placebo-pla-mtx-db","indication":"Rheumatoid arthritis (as part of control arm in Phase 3 trial)","status":"phase_3"},{"name":"Placebo matching Ipilimumab","genericName":"Placebo matching Ipilimumab","slug":"placebo-matching-ipilimumab","indication":"Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens","status":"phase_3"},{"name":"Placebo matching with Abatacept","genericName":"Placebo matching with Abatacept","slug":"placebo-matching-with-abatacept","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Reyataz","genericName":"ATAZANAVIR","slug":"atazanavir","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Subcutaneous (SC) abatacept","genericName":"Subcutaneous (SC) abatacept","slug":"subcutaneous-sc-abatacept","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Sustiva","genericName":"Sustiva","slug":"sustiva","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Sustiva","genericName":"EFAVIRENZ","slug":"efavirenz","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Videx","genericName":"DIDANOSINE","slug":"didanosine","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"abatacept (ABA)","genericName":"abatacept (ABA)","slug":"abatacept-aba","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":1785000000,"percentOfTotal":4.2,"drugCount":54,"colorKey":"neuroscience","drugs":[{"name":"Breyanzi","genericName":"LISOCABTAGENE MARALEUCEL","slug":"lisocabtagene-maraleucel","indication":"Other","status":"marketed","revenue":1358000000},{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","indication":"Other","status":"marketed","revenue":427000000},{"name":"BMS-986012","genericName":"BMS-986012","slug":"bms-986012","indication":"Other","status":"phase_2"},{"name":"BMS-986016","genericName":"BMS-986016","slug":"bms-986016","indication":"Other","status":"phase_2"},{"name":"BMS-986213","genericName":"BMS-986213","slug":"bms-986213","indication":"Other","status":"phase_2"},{"name":"BMS-986408","genericName":"BMS-986408","slug":"bms-986408","indication":"Other","status":"phase_1"},{"name":"BMS-986435","genericName":"BMS-986435","slug":"bms-986435","indication":"Other","status":"phase_2"},{"name":"Enteric Coated Mycophenolate Sodium","genericName":"Enteric Coated Mycophenolate Sodium","slug":"enteric-coated-mycophenolate-sodium","indication":"Other","status":"marketed"},{"name":"KarX-EC","genericName":"KarX-EC","slug":"karx-ec","indication":"Other","status":"phase_3"},{"name":"Veronate","genericName":"Veronate","slug":"veronate","indication":"Other","status":"phase_1"},{"name":"efavirenz, stavudine extended release, lamivudine","genericName":"efavirenz, stavudine extended release, lamivudine","slug":"efavirenz-stavudine-extended-release-lamivudine","indication":"Other","status":"marketed"},{"name":"Activated Charcoal with Sorbitol","genericName":"Activated Charcoal with Sorbitol","slug":"activated-charcoal-with-sorbitol","indication":"Management of acute poisoning","status":"phase_1"},{"name":"Active Pharmaceutical Ingredient","genericName":"Active Pharmaceutical Ingredient","slug":"active-pharmaceutical-ingredient","indication":"Other","status":"phase_1"},{"name":"Advanced therapy","genericName":"Advanced therapy","slug":"advanced-therapy","indication":"Other","status":"marketed"},{"name":"BMS-562086","genericName":"BMS-562086","slug":"bms-562086","indication":"Other","status":"phase_2"},{"name":"BMS-914392","genericName":"BMS-914392","slug":"bms-914392","indication":"Other","status":"phase_2"},{"name":"BMS-936558-01","genericName":"BMS-936558-01","slug":"bms-936558-01","indication":"Other","status":"phase_1"},{"name":"BMS-986142 200mg","genericName":"BMS-986142 200mg","slug":"bms-986142-200mg","indication":"Other","status":"phase_1"},{"name":"BMS-986166","genericName":"BMS-986166","slug":"bms-986166","indication":"Other","status":"phase_2"},{"name":"BMS-986207","genericName":"BMS-986207","slug":"bms-986207","indication":"Other","status":"phase_2"},{"name":"BMS-986259","genericName":"BMS-986259","slug":"bms-986259","indication":"Other","status":"phase_2"},{"name":"BMS-986322","genericName":"BMS-986322","slug":"bms-986322","indication":"Other","status":"phase_2"},{"name":"BMS-986340","genericName":"BMS-986340","slug":"bms-986340","indication":"Other","status":"phase_2"},{"name":"BMS-986446","genericName":"BMS-986446","slug":"bms-986446","indication":"Other","status":"phase_2"},{"name":"BMS-986458","genericName":"BMS-986458","slug":"bms-986458","indication":"Other","status":"phase_1"},{"name":"Belatacept LI (less intensive)","genericName":"Belatacept LI (less intensive)","slug":"belatacept-li-less-intensive","indication":"Prevention of organ rejection in kidney transplant recipients","status":"phase_3"},{"name":"Belatacept MI (more intensive)","genericName":"Belatacept MI (more intensive)","slug":"belatacept-mi-more-intensive","indication":"Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)","status":"phase_3"},{"name":"Brivanab","genericName":"Brivanab","slug":"brivanab","indication":"Other","status":"phase_1"},{"name":"CXL-1427","genericName":"CXL-1427","slug":"cxl-1427","indication":"Other","status":"phase_2"},{"name":"Cocktail","genericName":"Cocktail","slug":"cocktail","indication":"Other","status":"marketed"},{"name":"Delalutin","genericName":"HYDROXYPROGESTERONE CAPROATE","slug":"hydroxyprogesterone-caproate","indication":"Prevention of Premature Labor","status":"marketed"},{"name":"Dextrotubocurarine Chloride","genericName":"TUBOCURARINE","slug":"tubocurarine","indication":"Muscle relaxation, function","status":"marketed"},{"name":"Dilitazem","genericName":"Dilitazem","slug":"dilitazem","indication":"Other","status":"phase_1"},{"name":"Epivir","genericName":"Epivir","slug":"epivir","indication":"Other","status":"marketed"},{"name":"Etacillin","genericName":"HETACILLIN","slug":"hetacillin","indication":"Other","status":"marketed"},{"name":"Famotidine (FAM)","genericName":"Famotidine (FAM)","slug":"famotidine-fam","indication":"Duodenal ulcer","status":"marketed"},{"name":"IDO1 Inhibitor","genericName":"IDO1 Inhibitor","slug":"ido1-inhibitor","indication":"Other","status":"phase_1"},{"name":"Iza-bren","genericName":"Iza-bren","slug":"iza-bren","indication":"Other","status":"phase_2"},{"name":"Kinevac®","genericName":"Kinevac®","slug":"kinevac","indication":"Other","status":"marketed"},{"name":"Nulojix","genericName":"Nulojix","slug":"nulojix","indication":"Renal transplant rejection","status":"marketed"},{"name":"Nulojix","genericName":"BELATACEPT","slug":"belatacept","indication":"Renal transplant rejection","status":"marketed"},{"name":"OPDIVO QVANTIG","genericName":"HYALURONIDASE-NVHY","slug":"hyaluronidase-nvhy","indication":"Other","status":"marketed"},{"name":"Panolosetron","genericName":"Panolosetron","slug":"panolosetron","indication":"Other","status":"phase_1"},{"name":"Pemexetred","genericName":"Pemexetred","slug":"pemexetred","indication":"Other","status":"discontinued"},{"name":"Placebo for Nivolumab","genericName":"Placebo for Nivolumab","slug":"placebo-for-nivolumab","indication":"Control arm in Phase 3 clinical trials of Nivolumab","status":"phase_3"},{"name":"Placebo for apixaban","genericName":"Placebo for apixaban","slug":"placebo-for-apixaban","indication":"Control arm in apixaban clinical trials (specific indication depends on parent trial)","status":"phase_3"},{"name":"Placebo matching Dacarbazine","genericName":"Placebo matching Dacarbazine","slug":"placebo-matching-dacarbazine","indication":"Control arm in Phase 3 trial (specific indication unknown without trial protocol)","status":"phase_3"},{"name":"Placebo matching with Metformin XR","genericName":"Placebo matching with Metformin XR","slug":"placebo-matching-with-metformin-xr","indication":"Clinical trial control for studies evaluating Metformin XR efficacy and safety","status":"marketed"},{"name":"Prenisolone","genericName":"Prenisolone","slug":"prenisolone","indication":"Other","status":"phase_1"},{"name":"Regorafinib","genericName":"Regorafinib","slug":"regorafinib","indication":"Other","status":"phase_2"},{"name":"Ribasphere","genericName":"Ribasphere","slug":"ribasphere","indication":"Other","status":"phase_2"},{"name":"Treatment A: Mavacamten intact oral capsule","genericName":"Treatment A: Mavacamten intact oral capsule","slug":"treatment-a-mavacamten-intact-oral-capsule","indication":"Other","status":"phase_1"},{"name":"or Glyburide alone.","genericName":"or Glyburide alone.","slug":"or-glyburide-alone","indication":"Other","status":"marketed"},{"name":"panHer","genericName":"panHer","slug":"panher","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":41,"colorKey":"respiratory","drugs":[{"name":"Kanacin","genericName":"KANAMYCIN","slug":"kanamycin","indication":"Bacterial pneumonia","status":"marketed"},{"name":"Adefovir (ADV)","genericName":"Adefovir (ADV)","slug":"adefovir-adv","indication":"Chronic hepatitis B infection","status":"phase_3"},{"name":"Arikayce Kit","genericName":"AMIKACIN","slug":"amikacin","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Atazanavir + ritonavir + tenofovir + nucleoside","genericName":"Atazanavir + ritonavir + tenofovir + nucleoside","slug":"atazanavir-ritonavir-tenofovir-nucleoside","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Azactam","genericName":"AZTREONAM","slug":"aztreonam","indication":"Aerobic Gram-Negative Bacteremia","status":"marketed"},{"name":"Baraclude","genericName":"ENTECAVIR","slug":"entecavir","indication":"Chronic type B viral hepatitis","status":"marketed"},{"name":"DCV","genericName":"DCV","slug":"dcv","indication":"Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals","status":"phase_3"},{"name":"Daklinza","genericName":"DACLATASVIR","slug":"daclatasvir","indication":"Chronic hepatitis C","status":"marketed"},{"name":"LPV","genericName":"LPV","slug":"lpv","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Lopinavir/ritonavir + tenofovir + nucleoside","genericName":"Lopinavir/ritonavir + tenofovir + nucleoside","slug":"lopinavir-ritonavir-tenofovir-nucleoside","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Tenofovir/Emtricitabine","genericName":"Tenofovir/Emtricitabine","slug":"tenofovir-emtricitabine","indication":"HIV-1 infection (treatment)","status":"marketed"},{"name":"Unasyn","genericName":"AMPICILLIN","slug":"ampicillin","indication":"Acute bacterial epiglottitis","status":"marketed"},{"name":"Videx EC","genericName":"Videx EC","slug":"videx-ec","indication":"HIV-1 infection (in combination antiretroviral therapy)","status":"phase_3"},{"name":"stavudine extended-release, lamivudine, efavirenz","genericName":"stavudine extended-release, lamivudine, efavirenz","slug":"stavudine-extended-release-lamivudine-efavirenz","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"Adefovir/Entecavir","genericName":"Adefovir/Entecavir","slug":"adefovir-entecavir","indication":"Chronic hepatitis B infection","status":"marketed"},{"name":"Asunaprevir (ASV)","genericName":"Asunaprevir (ASV)","slug":"asunaprevir-asv","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1b","status":"phase_3"},{"name":"Atazanavir (Week 24 switch)","genericName":"Atazanavir (Week 24 switch)","slug":"atazanavir-week-24-switch","indication":"HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Atazanavir (immediate switch)","genericName":"Atazanavir (immediate switch)","slug":"atazanavir-immediate-switch","indication":"HIV-1 infection in treatment-naive and treatment-experienced adults","status":"phase_3"},{"name":"Atazanavir + 2 NRTIs","genericName":"Atazanavir + 2 NRTIs","slug":"atazanavir-2-nrtis","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir + Ritonavir + 2 NRTIs","genericName":"Atazanavir + Ritonavir + 2 NRTIs","slug":"atazanavir-ritonavir-2-nrtis","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Atazanavir + saquinavir + tenofovir + nucleoside","genericName":"Atazanavir + saquinavir + tenofovir + nucleoside","slug":"atazanavir-saquinavir-tenofovir-nucleoside","indication":"HIV-1 infection","status":"phase_3"},{"name":"Atazanavir capsules","genericName":"Atazanavir capsules","slug":"atazanavir-capsules","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","genericName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","slug":"atazanavir-ritonavir-stavidine-lamivudine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir/ Stavidine / Lamivudine","genericName":"Atazanavir/ Stavidine / Lamivudine","slug":"atazanavir-stavidine-lamivudine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Atazanavir/Ritonavir + Famotidine","genericName":"Atazanavir/Ritonavir + Famotidine","slug":"atazanavir-ritonavir-famotidine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Atazanvir/ritonavir + efavirenz","genericName":"Atazanvir/ritonavir + efavirenz","slug":"atazanvir-ritonavir-efavirenz","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"BECLABUVIR","genericName":"BECLABUVIR","slug":"beclabuvir","indication":"Chronic hepatitis C","status":"marketed"},{"name":"BMS-650032 (Asunaprevir)","genericName":"BMS-650032 (Asunaprevir)","slug":"bms-650032-asunaprevir","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1b","status":"phase_3"},{"name":"BMS-790052 (Daclatasvir)","genericName":"BMS-790052 (Daclatasvir)","slug":"bms-790052-daclatasvir","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"Baraclude","genericName":"Baraclude","slug":"baraclude","indication":"Chronic type B viral hepatitis","status":"marketed"},{"name":"Cefaprin","genericName":"cefapirin","slug":"cefapirin","indication":"Bacterial endocarditis","status":"marketed"},{"name":"Cefradex","genericName":"cefradine","slug":"cefradine","indication":"Acute otitis media","status":"marketed"},{"name":"DCV 3DAA","genericName":"DCV 3DAA","slug":"dcv-3daa","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"DCV/ASV/BMS-791325","genericName":"DCV/ASV/BMS-791325","slug":"dcv-asv-bms-791325","indication":"Chronic hepatitis C virus infection (genotype 1-6)","status":"phase_3"},{"name":"Lamivudine/Zidovudine","genericName":"Lamivudine/Zidovudine","slug":"lamivudine-zidovudine","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"marketed"},{"name":"Metacillin","genericName":"meticillin","slug":"meticillin","indication":"Bacterial septicemia","status":"marketed"},{"name":"Placebo matching BMS-790052","genericName":"Placebo matching BMS-790052","slug":"placebo-matching-bms-790052","indication":"Chronic hepatitis C virus infection (genotype 1)","status":"phase_3"},{"name":"Placebo matching Ribavirin","genericName":"Placebo matching Ribavirin","slug":"placebo-matching-ribavirin","indication":"Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)","status":"phase_3"},{"name":"REZIPAS","genericName":"AMINOSALICYLIC ACID RESIN COMPLEX","slug":"aminosalicylic-acid-resin-complex","indication":"Acute tuberculosis","status":"marketed"},{"name":"Ritonavir (heat-stable)","genericName":"Ritonavir (heat-stable)","slug":"ritonavir-heat-stable","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"},{"name":"stavudine, efavirenz, lamivudine","genericName":"stavudine, efavirenz, lamivudine","slug":"stavudine-efavirenz-lamivudine","indication":"HIV-1 infection","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"rare","drugs":[{"name":"Xanomeline Enteric Capsule","genericName":"Xanomeline Enteric Capsule","slug":"xanomeline-enteric-capsule","indication":"Alzheimer's disease","status":"phase_3"},{"name":"BMS-708163","genericName":"BMS-708163","slug":"bms-708163","indication":"Alzheimer's disease","status":"phase_2"},{"name":"Moditen Enanthate","genericName":"FLUPHENAZINE ENANTHATE","slug":"fluphenazine-enanthate","indication":"Psychotic disorder","status":"marketed"},{"name":"Prolixin Decanoate","genericName":"FLUPHENAZINE DECANOATE","slug":"fluphenazine-decanoate","indication":"Psychotic disorder","status":"marketed"},{"name":"Serzone","genericName":"NEFAZODONE","slug":"nefazodone","indication":"Major depressive disorder","status":"marketed"},{"name":"Antidepressant + Aripiprazole","genericName":"Antidepressant + Aripiprazole","slug":"antidepressant-aripiprazole","indication":"Major depressive disorder, treatment-resistant or inadequate response to antidepressant monotherapy","status":"phase_3"},{"name":"Aurexis®","genericName":"Aurexis®","slug":"aurexis","indication":"Major depressive disorder","status":"phase_2"},{"name":"Extended Phenytoin Sodium","genericName":"Extended Phenytoin Sodium","slug":"extended-phenytoin-sodium","indication":"Generalized tonic-clonic seizures","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Acetadote","genericName":"Acetylcysteine","slug":"acetylcysteine","indication":"Amyloidosis","status":"marketed"},{"name":"Corticosteroid: Triamcinolone","genericName":"Corticosteroid: Triamcinolone","slug":"corticosteroid-triamcinolone","indication":"Nephrotic syndrome","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Placebo matching with Metformin IR","genericName":"Placebo matching with Metformin IR","slug":"placebo-matching-with-metformin-ir","indication":"Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders","status":"marketed"},{"name":"or Metformin HCl alone","genericName":"or Metformin HCl alone","slug":"or-metformin-hcl-alone","indication":"Type 2 diabetes mellitus","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Ortho Tri-Cyclen LO","genericName":"Ortho Tri-Cyclen LO","slug":"ortho-tri-cyclen-lo","indication":"Contraception (pregnancy prevention)","status":"marketed"}]}],"pipeline":[{"name":"Eliquis","genericName":"apixaban","slug":"apixaban","phase":"marketed","mechanism":"Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.","indications":["Arterial embolus and thrombosis","Myocardial Reinfarction Prevention"],"catalyst":""},{"name":"Opdivo","genericName":"nivolumab","slug":"nivolumab","phase":"marketed","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.","indications":["Advanced melanoma with tumour cell PD-L1 expression below 1%","Classical Hodgkin lymphoma","Head and neck cancer","Malignant tumor of esophagus","Malignant tumor of stomach"],"catalyst":""},{"name":"Revlimid","genericName":"lenalidomide","slug":"lenalidomide","phase":"marketed","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation.","indications":["Follicular lymphoma","Mantle cell lymphoma","Marginal zone lymphoma","Multiple myeloma","Myelodysplastic syndrome"],"catalyst":""},{"name":"Orencia","genericName":"abatacept","slug":"abatacept","phase":"marketed","mechanism":"Abatacept inhibits T-cell activation by binding CD80/CD86, blocking CD28 costimulatory interaction.","indications":["Juvenile idiopathic arthritis","Rheumatoid arthritis"],"catalyst":""},{"name":"Yervoy","genericName":"ipilimumab","slug":"ipilimumab","phase":"discontinued","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells.","indications":["High grade squamous intraepithelial neoplasia of esophagus","Metastatic malignant melanoma","Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","Microsatellite instability-high colorectal cancer","Renal cell carcinoma"],"catalyst":""},{"name":"Pomalyst","genericName":"pomalidomide","slug":"pomalidomide","phase":"marketed","mechanism":"Pomalyst works by binding to the cereblon protein, which disrupts the function of certain genes involved in cancer cell growth.","indications":["Multiple myeloma"],"catalyst":""},{"name":"Breyanzi","genericName":"LISOCABTAGENE MARALEUCEL","slug":"lisocabtagene-maraleucel","phase":"marketed","mechanism":"Gene therapy","indications":[],"catalyst":""},{"name":"Zeposia","genericName":"OZANIMOD","slug":"ozanimod","phase":"marketed","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression.","indications":["Multiple sclerosis","Relapsing remitting multiple sclerosis","Ulcerative colitis"],"catalyst":""},{"name":"Camzyos","genericName":"MAVACAMTEN","slug":"mavacamten","phase":"marketed","mechanism":"Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.","indications":["Obstructive hypertrophic cardiomyopathy (HCM)"],"catalyst":""},{"name":"Abecma","genericName":"idecabtagene vicleucel","slug":"idecabtagene-vicleucel","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Sotyktu","genericName":"DEUCRAVACITINIB","slug":"deucravacitinib","phase":"marketed","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis.","indications":["Moderate-to-severe plaque psoriasis","Active psoriatic arthritis"],"catalyst":""},{"name":"Krazati","genericName":"ADAGRASIB","slug":"adagrasib","phase":"marketed","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth.","indications":["KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Acetadote","genericName":"Acetylcysteine","slug":"acetylcysteine","phase":"marketed","mechanism":"Acetylcysteine reduces liver injury from acetaminophen overdose by maintaining glutathione levels or providing alternate conjugation substrate.","indications":["Amyloidosis","Atelectasis due to Mucous Obstruction","Bronchiectasis","Bronchitis","Contrast Media-Induced Nephrotoxicity Prevention"],"catalyst":""},{"name":"Huluc63","genericName":"elotuzumab","slug":"elotuzumab","phase":"marketed","mechanism":"Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells.","indications":["Multiple myeloma","Relapse multiple myeloma"],"catalyst":""},{"name":"Vidaza","genericName":"azacitidine","slug":"azacitidine","phase":"marketed","mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells.","indications":["Refractory Anemia (RA)","Refractory Anemia with Ringed Sideroblasts (RARS)","Refractory Anemia with Excess Blasts (RAEB)","Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","Chronic Myelomonocytic Leukemia (CMMoL)"],"catalyst":""},{"name":"Vepesid","genericName":"etoposide","slug":"etoposide","phase":"marketed","mechanism":"DNA topoisomerase 2-alpha","indications":["Malignant tumor of testis","Small cell carcinoma of lung","Treatment prior to tumor-specific T-cell infusion therapy"],"catalyst":""},{"name":"BMS-986012","genericName":"BMS-986012","slug":"bms-986012","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986278","genericName":"BMS-986278","slug":"bms-986278","phase":"phase_3","mechanism":"BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","indications":["Acute coronary syndrome","Chronic kidney disease"],"catalyst":""},{"name":"Kanacin","genericName":"KANAMYCIN","slug":"kanamycin","phase":"marketed","mechanism":"Gap junction beta-2 protein","indications":["Bacterial pneumonia","Bacterial septicemia","Burn Wound Infections","Cholangitis","Infection of bone"],"catalyst":""},{"name":"Ramipril + Irbesartan","genericName":"Ramipril + Irbesartan","slug":"ramipril-irbesartan","phase":"marketed","mechanism":"This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism.","indications":["Hypertension in patients not adequately controlled on monotherapy"],"catalyst":""},{"name":"Xanomeline Enteric Capsule","genericName":"Xanomeline Enteric Capsule","slug":"xanomeline-enteric-capsule","phase":"phase_3","mechanism":"Xanomeline is a muscarinic receptor agonist that targets the M1 and M4 subtypes.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Adefovir (ADV)","genericName":"Adefovir (ADV)","slug":"adefovir-adv","phase":"phase_3","mechanism":"Adefovir is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase, preventing replication of hepatitis B virus.","indications":["Chronic hepatitis B infection","HBV with lamivudine resistance"],"catalyst":""},{"name":"Arikayce Kit","genericName":"AMIKACIN","slug":"amikacin","phase":"marketed","mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.","indications":["Bacterial infection due to Klebsiella pneumoniae","Bacterial infection due to Serratia","Bacterial meningitis","Bacterial meningitis due to Gram-negative bacteria","Bacterial pneumonia"],"catalyst":""},{"name":"Atazanavir + ritonavir + tenofovir + nucleoside","genericName":"Atazanavir + ritonavir + tenofovir + nucleoside","slug":"atazanavir-ritonavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication in HIV-infected patients.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Azactam","genericName":"AZTREONAM","slug":"aztreonam","phase":"marketed","mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent.","indications":["Aerobic Gram-Negative Bacteremia","Bacterial Exacerbation of Acute Bronchitis","Bacterial infection due to Klebsiella pneumoniae","Bacterial infection due to Serratia","Bacterial peritonitis"],"catalyst":""},{"name":"BMS-708163","genericName":"BMS-708163","slug":"bms-708163","phase":"phase_2","mechanism":"BMS-708163 inhibits the activity of beta-secretase (BACE1), an enzyme involved in the production of amyloid-beta peptides, which are associated with Alzheimer's disease.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"BMS-986016","genericName":"BMS-986016","slug":"bms-986016","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986165","genericName":"BMS-986165","slug":"bms-986165","phase":"marketed","mechanism":"BMS-986165 is a selective inhibitor of the interleukin-12 and interleukin-23 (IL-12/IL-23) p40 subunit that reduces inflammatory signaling in immune-mediated diseases.","indications":["Psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"BMS-986205","genericName":"BMS-986205","slug":"bms-986205","phase":"phase_3","mechanism":"BMS-986205 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","indications":["Acute coronary syndrome","Chronic kidney disease"],"catalyst":""},{"name":"BMS-986213","genericName":"BMS-986213","slug":"bms-986213","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BMS-986231","genericName":"BMS-986231","slug":"bms-986231","phase":"phase_2","mechanism":"BMS-986231 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"BMS-986374","genericName":"BMS-986374","slug":"bms-986374","phase":"marketed","mechanism":"BMS-986374 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) that blocks symmetric dimethylarginine formation on target proteins.","indications":["Metastatic non-small cell lung cancer (NSCLC) with MTAP deletion","Other solid tumors with MTAP loss or PRMT5 dependency"],"catalyst":""},{"name":"BMS-986408","genericName":"BMS-986408","slug":"bms-986408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986435","genericName":"BMS-986435","slug":"bms-986435","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baraclude","genericName":"ENTECAVIR","slug":"entecavir","phase":"marketed","mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus.","indications":["Chronic type B viral hepatitis","Lamivudine-Refractory Chronic Hepatitis B"],"catalyst":""},{"name":"Blenoxane","genericName":"BLEOMYCIN","slug":"bleomycin","phase":"marketed","mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death.","indications":["Diffuse non-Hodgkin's lymphoma, large cell","Follicular non-Hodgkin's lymphoma","Hodgkin's disease","International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma","Malignant tumor of cervix"],"catalyst":""},{"name":"Cetuximab/Erbitux","genericName":"Cetuximab/Erbitux","slug":"cetuximab-erbitux","phase":"phase_3","mechanism":"Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.","indications":["Metastatic colorectal cancer (KRAS wild-type)","Head and neck squamous cell carcinoma","Non-small cell lung cancer (EGFR-expressing)"],"catalyst":""},{"name":"DCV","genericName":"DCV","slug":"dcv","phase":"phase_3","mechanism":"DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals"],"catalyst":""},{"name":"Daklinza","genericName":"DACLATASVIR","slug":"daclatasvir","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"Enteric Coated Mycophenolate Sodium","genericName":"Enteric Coated Mycophenolate Sodium","slug":"enteric-coated-mycophenolate-sodium","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HCTZ monotherapy","genericName":"HCTZ monotherapy","slug":"hctz-monotherapy","phase":"phase_3","mechanism":"HCTZ (hydrochlorothiazide) is a thiazide diuretic that reduces blood pressure by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney.","indications":["Hypertension","Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease"],"catalyst":""},{"name":"Idhifa","genericName":"ENASIDENIB","slug":"enasidenib","phase":"marketed","mechanism":"Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth.","indications":["Acute myeloid leukemia, disease"],"catalyst":""},{"name":"Immunotherapy monotherapy","genericName":"Immunotherapy monotherapy","slug":"immunotherapy-monotherapy","phase":"phase_2","mechanism":"Immune checkpoint inhibitor","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Inrebic","genericName":"FEDRATINIB","slug":"fedratinib","phase":"marketed","mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells.","indications":["Myelofibrosis","Post-essential thrombocythaemia myelofibrosis","Post-polycythaemia vera myelofibrosis","Primary myelofibrosis"],"catalyst":""},{"name":"KarX-EC","genericName":"KarX-EC","slug":"karx-ec","phase":"phase_3","mechanism":"KarX-EC is an extended-release formulation designed to improve the pharmacokinetic profile and therapeutic delivery of its active component.","indications":[],"catalyst":""},{"name":"LPV","genericName":"LPV","slug":"lpv","phase":"phase_3","mechanism":"LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","COVID-19 (investigational use in phase 3)"],"catalyst":""},{"name":"Lopinavir/ritonavir + tenofovir + nucleoside","genericName":"Lopinavir/ritonavir + tenofovir + nucleoside","slug":"lopinavir-ritonavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Moditen Enanthate","genericName":"FLUPHENAZINE ENANTHATE","slug":"fluphenazine-enanthate","phase":"marketed","mechanism":"D(3) dopamine receptor","indications":["Psychotic disorder","Schizophrenia"],"catalyst":""},{"name":"OPDUALAG","genericName":"RELATLIMAB-RMBW","slug":"relatlimab-rmbw","phase":"marketed","mechanism":"Lymphocyte activation gene 3 protein","indications":["Advanced melanoma with tumour cell PD-L1 expression below 1%","Unresectable or metastatic melanoma"],"catalyst":""},{"name":"Placebo matching with Metformin IR","genericName":"Placebo matching with Metformin IR","slug":"placebo-matching-with-metformin-ir","phase":"marketed","mechanism":"This is a placebo-matched formulation used in clinical trials to maintain blinding while comparing against Metformin IR (immediate-release), which reduces hepatic glucose production and improves insulin sensitivity.","indications":["Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders"],"catalyst":""},{"name":"Prolixin Decanoate","genericName":"FLUPHENAZINE DECANOATE","slug":"fluphenazine-decanoate","phase":"marketed","mechanism":"D(2) dopamine receptor","indications":["Psychotic disorder","Schizophrenia"],"catalyst":""},{"name":"Serzone","genericName":"NEFAZODONE","slug":"nefazodone","phase":"marketed","mechanism":"Sodium-dependent serotonin transporter","indications":["Major depressive disorder"],"catalyst":""},{"name":"Tenofovir/Emtricitabine","genericName":"Tenofovir/Emtricitabine","slug":"tenofovir-emtricitabine","phase":"marketed","mechanism":"Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.","indications":["HIV-1 infection (treatment)","HIV-1 pre-exposure prophylaxis (PrEP)"],"catalyst":""},{"name":"Unasyn","genericName":"AMPICILLIN","slug":"ampicillin","phase":"marketed","mechanism":"Transient receptor potential cation channel subfamily M member 4","indications":["Acute bacterial epiglottitis","Acute bacterial sinusitis","Acute epiglottitis","Acute exacerbation of chronic bronchitis","Acute gonococcal cervicitis"],"catalyst":""},{"name":"Veronate","genericName":"Veronate","slug":"veronate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Videx EC","genericName":"Videx EC","slug":"videx-ec","phase":"phase_3","mechanism":"Videx EC is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.","indications":["HIV-1 infection (in combination antiretroviral therapy)"],"catalyst":""},{"name":"efavirenz, stavudine extended release, lamivudine","genericName":"efavirenz, stavudine extended release, lamivudine","slug":"efavirenz-stavudine-extended-release-lamivudine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"stavudine extended-release, lamivudine, efavirenz","genericName":"stavudine extended-release, lamivudine, efavirenz","slug":"stavudine-extended-release-lamivudine-efavirenz","phase":"phase_3","mechanism":"Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of HIV-1 infection in adults and children"],"catalyst":""},{"name":"ABA, open-label (OL)","genericName":"ABA, open-label (OL)","slug":"aba-open-label-ol","phase":"phase_3","mechanism":"Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","indications":["Metastatic melanoma","Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Abatacept subcutaneous","genericName":"Abatacept subcutaneous","slug":"abatacept-subcutaneous","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Activated Charcoal with Sorbitol","genericName":"Activated Charcoal with Sorbitol","slug":"activated-charcoal-with-sorbitol","phase":"phase_1","mechanism":"Activated charcoal adsorbs toxins and excess gases in the gastrointestinal tract, while sorbitol acts as a laxative to facilitate their removal.","indications":["Management of acute poisoning","Relief of bloating and gas"],"catalyst":""},{"name":"Active Pharmaceutical Ingredient","genericName":"Active Pharmaceutical Ingredient","slug":"active-pharmaceutical-ingredient","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adefovir/Entecavir","genericName":"Adefovir/Entecavir","slug":"adefovir-entecavir","phase":"marketed","mechanism":"Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.","indications":["Chronic hepatitis B infection","Lamivudine-resistant hepatitis B (adefovir)"],"catalyst":""},{"name":"Advanced therapy","genericName":"Advanced therapy","slug":"advanced-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anti-IL8","genericName":"Anti-IL8","slug":"anti-il8","phase":"phase_2","mechanism":"Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity.","indications":["Moderate to severe chronic plaque psoriasis","Rheumatoid arthritis"],"catalyst":""},{"name":"Anti-IP-10 Antibody","genericName":"Anti-IP-10 Antibody","slug":"anti-ip-10-antibody","phase":"phase_2","mechanism":"Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.","indications":["Psoriasis"],"catalyst":""},{"name":"Antidepressant + Aripiprazole","genericName":"Antidepressant + Aripiprazole","slug":"antidepressant-aripiprazole","phase":"phase_3","mechanism":"This combination enhances serotonergic and noradrenergic neurotransmission via antidepressant action while aripiprazole provides dopaminergic stabilization and augmentation of antidepressant efficacy.","indications":["Major depressive disorder, treatment-resistant or inadequate response to antidepressant monotherapy"],"catalyst":""},{"name":"Any biologic treatment for psoriasis","genericName":"Any biologic treatment for psoriasis","slug":"any-biologic-treatment-for-psoriasis","phase":"phase_2","mechanism":"Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.","indications":["Moderate to severe plaque psoriasis","Moderate to severe scalp psoriasis"],"catalyst":""},{"name":"Approved Hypertrophic Cardiomyopathy drug treatments","genericName":"Approved Hypertrophic Cardiomyopathy drug treatments","slug":"approved-hypertrophic-cardiomyopathy-drug-treatments","phase":"phase_2","mechanism":"Calcium channel blocker","indications":["Hypertrophic cardiomyopathy"],"catalyst":""},{"name":"Asunaprevir (ASV)","genericName":"Asunaprevir (ASV)","slug":"asunaprevir-asv","phase":"phase_3","mechanism":"Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1b"],"catalyst":""},{"name":"Atazanavir (Week 24 switch)","genericName":"Atazanavir (Week 24 switch)","slug":"atazanavir-week-24-switch","phase":"phase_3","mechanism":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.","indications":["HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Atazanavir (immediate switch)","genericName":"Atazanavir (immediate switch)","slug":"atazanavir-immediate-switch","phase":"phase_3","mechanism":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced adults","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Atazanavir + 2 NRTIs","genericName":"Atazanavir + 2 NRTIs","slug":"atazanavir-2-nrtis","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection as part of combination antiretroviral therapy"],"catalyst":""},{"name":"Atazanavir + Ritonavir + 2 NRTIs","genericName":"Atazanavir + Ritonavir + 2 NRTIs","slug":"atazanavir-ritonavir-2-nrtis","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and the two NRTIs inhibit reverse transcriptase to block HIV DNA synthesis.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"Atazanavir + saquinavir + tenofovir + nucleoside","genericName":"Atazanavir + saquinavir + tenofovir + nucleoside","slug":"atazanavir-saquinavir-tenofovir-nucleoside","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Atazanavir capsules","genericName":"Atazanavir capsules","slug":"atazanavir-capsules","phase":"phase_3","mechanism":"Atazanavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","genericName":"Atazanavir-Ritonavir/ Stavidine / Lamivudine","slug":"atazanavir-ritonavir-stavidine-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps in the HIV life cycle.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Atazanavir/ Stavidine / Lamivudine","genericName":"Atazanavir/ Stavidine / Lamivudine","slug":"atazanavir-stavidine-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV replication by blocking reverse transcriptase and protease enzymes required for viral reproduction.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Atazanavir/Ritonavir + Famotidine","genericName":"Atazanavir/Ritonavir + Famotidine","slug":"atazanavir-ritonavir-famotidine","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""},{"name":"Atazanvir/ritonavir + efavirenz","genericName":"Atazanvir/ritonavir + efavirenz","slug":"atazanvir-ritonavir-efavirenz","phase":"phase_3","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Aurexis®","genericName":"Aurexis®","slug":"aurexis","phase":"phase_2","mechanism":"Selective serotonin reuptake inhibitor","indications":["Major depressive disorder"],"catalyst":""},{"name":"BECLABUVIR","genericName":"BECLABUVIR","slug":"beclabuvir","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"BET Inhibitor","genericName":"BET Inhibitor","slug":"bet-inhibitor","phase":"phase_2","mechanism":"BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins","indications":["T-cell lymphoma","Multiple myeloma"],"catalyst":""},{"name":"BMS-562086","genericName":"BMS-562086","slug":"bms-562086","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-650032","genericName":"BMS-650032","slug":"bms-650032","phase":"phase_2","mechanism":"BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"BMS-650032 (Asunaprevir)","genericName":"BMS-650032 (Asunaprevir)","slug":"bms-650032-asunaprevir","phase":"phase_3","mechanism":"Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1b"],"catalyst":""},{"name":"BMS-790052","genericName":"BMS-790052","slug":"bms-790052","phase":"phase_2","mechanism":"BMS-790052 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck cancer"],"catalyst":""},{"name":"BMS-790052 (Daclatasvir)","genericName":"BMS-790052 (Daclatasvir)","slug":"bms-790052-daclatasvir","phase":"phase_3","mechanism":"Daclatasvir inhibits the hepatitis C virus NS5A protein, blocking viral replication and spread.","indications":["Chronic hepatitis C virus infection (genotype 1-6)","Hepatitis C in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"BMS-914392","genericName":"BMS-914392","slug":"bms-914392","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-936558 (Nivolumab)","genericName":"BMS-936558 (Nivolumab)","slug":"bms-936558-nivolumab","phase":"phase_3","mechanism":"Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Advanced non-small cell lung cancer","Renal cell carcinoma","Classical Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"BMS-936558-01","genericName":"BMS-936558-01","slug":"bms-936558-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-954561","genericName":"BMS-954561","slug":"bms-954561","phase":"phase_2","mechanism":"BMS-954561 is a small molecule that targets the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"BMS-986142 200mg","genericName":"BMS-986142 200mg","slug":"bms-986142-200mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986165 Dose A","genericName":"BMS-986165 Dose A","slug":"bms-986165-dose-a","phase":"phase_2","mechanism":"BMS-986165 Dose A is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"BMS-986165 Dose B","genericName":"BMS-986165 Dose B","slug":"bms-986165-dose-b","phase":"phase_2","mechanism":"BMS-986165 is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, thereby enhancing the immune response against cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"BMS-986166","genericName":"BMS-986166","slug":"bms-986166","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986177","genericName":"BMS-986177","slug":"bms-986177","phase":"phase_2","mechanism":"BMS-986177 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"BMS-986207","genericName":"BMS-986207","slug":"bms-986207","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986259","genericName":"BMS-986259","slug":"bms-986259","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986322","genericName":"BMS-986322","slug":"bms-986322","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986340","genericName":"BMS-986340","slug":"bms-986340","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986446","genericName":"BMS-986446","slug":"bms-986446","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986458","genericName":"BMS-986458","slug":"bms-986458","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMS-986504","genericName":"BMS-986504","slug":"bms-986504","phase":"phase_2","mechanism":"BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Baraclude","genericName":"Baraclude","slug":"baraclude","phase":"marketed","mechanism":"Capsid protein, Protein P, Protein P","indications":["Chronic type B viral hepatitis","Lamivudine-Refractory Chronic Hepatitis B"],"catalyst":""},{"name":"Belatacept LI (less intensive)","genericName":"Belatacept LI (less intensive)","slug":"belatacept-li-less-intensive","phase":"phase_3","mechanism":"Belatacept is a selective T-cell costimulation blocker that inhibits T-cell activation by binding to CD80/CD86 on antigen-presenting cells.","indications":["Prevention of organ rejection in kidney transplant recipients"],"catalyst":""},{"name":"Belatacept MI (more intensive)","genericName":"Belatacept MI (more intensive)","slug":"belatacept-mi-more-intensive","phase":"phase_3","mechanism":"Belatacept is a selective T-cell costimulation blocker that inhibits CD80/CD86 binding to CD28, preventing T-cell activation and proliferation.","indications":["Prevention of organ rejection in kidney transplant recipients (Phase 3 evaluation of intensive dosing regimen)"],"catalyst":""},{"name":"Brivanab","genericName":"Brivanab","slug":"brivanab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CXL-1427","genericName":"CXL-1427","slug":"cxl-1427","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carboplatin/Paraplatin","genericName":"Carboplatin/Paraplatin","slug":"carboplatin-paraplatin","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing cell death.","indications":["Ovarian cancer","Non-small cell lung cancer","Small cell lung cancer","Head and neck cancer","Breast cancer"],"catalyst":""},{"name":"Cefaprin","genericName":"cefapirin","slug":"cefapirin","phase":"marketed","mechanism":"Sigma non-opioid intracellular receptor 1","indications":["Bacterial endocarditis","Bacterial infection due to Klebsiella pneumoniae","Bacterial septicemia","Escherichia coli urinary tract infection","Haemophilus influenzae pneumonia"],"catalyst":""},{"name":"Cefradex","genericName":"cefradine","slug":"cefradine","phase":"marketed","mechanism":"Matrix metalloproteinase-9","indications":["Acute otitis media","Bacterial infection due to Klebsiella pneumoniae","Enterococcus Prostatitis","Enterococcus Urinary Tract Infection","Escherichia coli urinary tract infection"],"catalyst":""},{"name":"Cisplatin/Platinol","genericName":"Cisplatin/Platinol","slug":"cisplatin-platinol","phase":"phase_3","mechanism":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and triggering cancer cell death.","indications":["Metastatic testicular cancer","Metastatic ovarian cancer","Advanced bladder cancer","Head and neck cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Cocktail","genericName":"Cocktail","slug":"cocktail","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Corticosteroid: Meprednisone","genericName":"Corticosteroid: Meprednisone","slug":"corticosteroid-meprednisone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Treatment of various cancers"],"catalyst":""},{"name":"Corticosteroid: Methylprednisolone","genericName":"Corticosteroid: Methylprednisolone","slug":"corticosteroid-methylprednisolone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Multiple sclerosis","Rheumatoid arthritis","Asthma"],"catalyst":""},{"name":"Corticosteroid: Prednisone","genericName":"Corticosteroid: Prednisone","slug":"corticosteroid-prednisone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Rheumatoid arthritis","Asthma","Multiple sclerosis"],"catalyst":""},{"name":"Corticosteroid: Triamcinolone","genericName":"Corticosteroid: Triamcinolone","slug":"corticosteroid-triamcinolone","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Nephrotic syndrome","Severe asthma","Severe allergies"],"catalyst":""},{"name":"DCV 3DAA","genericName":"DCV 3DAA","slug":"dcv-3daa","phase":"phase_3","mechanism":"DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6)"],"catalyst":""},{"name":"DCV/ASV/BMS-791325","genericName":"DCV/ASV/BMS-791325","slug":"dcv-asv-bms-791325","phase":"phase_3","mechanism":"This is a three-drug combination of direct-acting antivirals (DCV, ASV, and BMS-791325) that inhibit hepatitis C virus NS5A, NS3 protease, and NS5B polymerase respectively to block viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1-6)"],"catalyst":""},{"name":"Delalutin","genericName":"HYDROXYPROGESTERONE CAPROATE","slug":"hydroxyprogesterone-caproate","phase":"marketed","mechanism":"Corticosteroid-binding globulin","indications":["Prevention of Premature Labor"],"catalyst":""},{"name":"Dextrotubocurarine Chloride","genericName":"TUBOCURARINE","slug":"tubocurarine","phase":"marketed","mechanism":"Acetylcholine receptor","indications":["Muscle relaxation, function"],"catalyst":""},{"name":"Dilitazem","genericName":"Dilitazem","slug":"dilitazem","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Double-blind Abatacept","genericName":"Double-blind Abatacept","slug":"double-blind-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Epivir","genericName":"Epivir","slug":"epivir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Etacillin","genericName":"HETACILLIN","slug":"hetacillin","phase":"marketed","mechanism":"Penicillin-binding protein","indications":[],"catalyst":""},{"name":"Extended Phenytoin Sodium","genericName":"Extended Phenytoin Sodium","slug":"extended-phenytoin-sodium","phase":"marketed","mechanism":"Extended-release phenytoin sodium blocks voltage-gated sodium channels in the brain to reduce neuronal excitability and prevent seizure propagation.","indications":["Generalized tonic-clonic seizures","Complex partial (temporal lobe) seizures","Simple partial seizures","Status epilepticus (parenteral formulation)"],"catalyst":""},{"name":"Famotidine (FAM)","genericName":"Famotidine (FAM)","slug":"famotidine-fam","phase":"marketed","mechanism":"Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach.","indications":["Duodenal ulcer","Gastric ulcer","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome","Peptic ulcer disease prophylaxis"],"catalyst":""},{"name":"Fluorouracil/Adrucil","genericName":"Fluorouracil/Adrucil","slug":"fluorouracil-adrucil","phase":"phase_3","mechanism":"Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"IDO1 Inhibitor","genericName":"IDO1 Inhibitor","slug":"ido1-inhibitor","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Infliximab (INF) + MTX, DB","genericName":"Infliximab (INF) + MTX, DB","slug":"infliximab-inf-mtx-db","phase":"phase_3","mechanism":"Infliximab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling, while methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) that inhibits folate metabolism and immune cell proliferation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Inrebic","genericName":"FEDRATINIB HYDROCHLORIDE","slug":"fedratinib-hydrochloride","phase":"marketed","mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs.","indications":["Myelofibrosis","Post-essential thrombocythaemia myelofibrosis","Post-polycythaemia vera myelofibrosis","Primary myelofibrosis"],"catalyst":""},{"name":"Intravenous (IV) abatacept","genericName":"Intravenous (IV) abatacept","slug":"intravenous-iv-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Irbesartan monotherapy","genericName":"Irbesartan monotherapy","slug":"irbesartan-monotherapy","phase":"phase_3","mechanism":"Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes and hypertension"],"catalyst":""},{"name":"Irbesartan/HCTZ","genericName":"Irbesartan/HCTZ","slug":"irbesartan-hctz","phase":"phase_3","mechanism":"Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.","indications":["Hypertension (high blood pressure)","Reduction of cardiovascular events in hypertensive patients at high risk"],"catalyst":""},{"name":"Iza-bren","genericName":"Iza-bren","slug":"iza-bren","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Kinevac®","genericName":"Kinevac®","slug":"kinevac","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lamivudine/Zidovudine","genericName":"Lamivudine/Zidovudine","slug":"lamivudine-zidovudine","phase":"marketed","mechanism":"This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Megace","genericName":"MEGESTROL ACETATE","slug":"megestrol-acetate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Anorexia from HIV","Cachexia due to HIV","Endometrial carcinoma","Hormone receptor positive malignant neoplasm of breast","Nutritional deficiency associated with AIDS"],"catalyst":""},{"name":"Metacillin","genericName":"meticillin","slug":"meticillin","phase":"marketed","mechanism":"","indications":["Bacterial septicemia","Infection of skin AND/OR subcutaneous tissue","Sinusitis","Staphylococcal pneumonia"],"catalyst":""},{"name":"NKTR-214","genericName":"NKTR-214","slug":"nktr-214","phase":"phase_3","mechanism":"NKTR-214 is an engineered interleukin-2 (IL-2) cytokine that preferentially activates and expands CD8+ T cells and NK cells to enhance anti-tumor immune responses.","indications":["Metastatic melanoma (in combination with nivolumab)","Renal cell carcinoma (in combination with nivolumab)","Non-small cell lung cancer (in combination with nivolumab)"],"catalyst":""},{"name":"Nitroglycerin (NTG)","genericName":"Nitroglycerin (NTG)","slug":"nitroglycerin-ntg","phase":"marketed","mechanism":"Nitroglycerin is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and dilate blood vessels, reducing cardiac preload and afterload.","indications":["Acute angina pectoris (sublingual/spray formulation)","Chronic stable angina (long-acting formulations)","Acute myocardial infarction","Heart failure with pulmonary edema"],"catalyst":""},{"name":"Nivolumab and rHuPH20","genericName":"Nivolumab and rHuPH20","slug":"nivolumab-and-rhuph20","phase":"phase_3","mechanism":"Nivolumab blocks PD-1 on immune cells to restore anti-tumor immunity, while rHuPH20 (recombinant human hyaluronidase) enhances drug penetration into tumors by degrading the hyaluronic acid-rich extracellular matrix.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Nivolumab in combination with Ipilimumab","genericName":"Nivolumab in combination with Ipilimumab","slug":"nivolumab-in-combination-with-ipilimumab","phase":"marketed","mechanism":"Nivolumab and ipilimumab together block two different immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses.","indications":["Metastatic melanoma","Advanced renal cell carcinoma","Metastatic non-small cell lung cancer","Malignant pleural mesothelioma","Hepatocellular carcinoma"],"catalyst":""},{"name":"Nivolumab-relatlimab FDC","genericName":"Nivolumab-relatlimab FDC","slug":"nivolumab-relatlimab-fdc","phase":"phase_3","mechanism":"This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.","indications":["Melanoma (advanced or metastatic)","Non-small cell lung cancer"],"catalyst":""},{"name":"Nivolumab/rHuPH20","genericName":"Nivolumab/rHuPH20","slug":"nivolumab-rhuph20","phase":"phase_3","mechanism":"Nivolumab is a PD-1 inhibitor that blocks immune checkpoint signaling, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous drug delivery and bioavailability.","indications":["Metastatic melanoma","Non-small cell lung cancer","Renal cell carcinoma","Hodgkin lymphoma","Squamous cell carcinoma of the head and neck"],"catalyst":""},{"name":"Nulojix","genericName":"Nulojix","slug":"nulojix","phase":"marketed","mechanism":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","indications":["Renal transplant rejection"],"catalyst":""},{"name":"Nulojix","genericName":"BELATACEPT","slug":"belatacept","phase":"marketed","mechanism":"Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response.","indications":["Renal transplant rejection"],"catalyst":""},{"name":"OPDIVO QVANTIG","genericName":"HYALURONIDASE-NVHY","slug":"hyaluronidase-nvhy","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Open-label Abatacept","genericName":"Open-label Abatacept","slug":"open-label-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Orencia","genericName":"Orencia","slug":"orencia","phase":"marketed","mechanism":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","indications":["Juvenile idiopathic arthritis","Rheumatoid arthritis"],"catalyst":""},{"name":"Ortho Tri-Cyclen LO","genericName":"Ortho Tri-Cyclen LO","slug":"ortho-tri-cyclen-lo","phase":"marketed","mechanism":"Ortho Tri-Cyclen LO is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of norgestimate and ethinyl estradiol.","indications":["Contraception (pregnancy prevention)","Acne vulgaris (FDA-approved indication)"],"catalyst":""},{"name":"PLA + MTX switched to ABA+ MTX, DB","genericName":"PLA + MTX switched to ABA+ MTX, DB","slug":"pla-mtx-switched-to-aba-mtx-db","phase":"phase_3","mechanism":"Abatacept (ABA) is a T-cell costimulation inhibitor that blocks the interaction between antigen-presenting cells and T cells, reducing inflammatory immune responses when combined with methotrexate (MTX).","indications":["Rheumatoid arthritis (as part of combination therapy with MTX)","Polyarticular juvenile idiopathic arthritis"],"catalyst":""},{"name":"Panolosetron","genericName":"Panolosetron","slug":"panolosetron","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pemexetred","genericName":"Pemexetred","slug":"pemexetred","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo (PLA) + MTX, DB","genericName":"Placebo (PLA) + MTX, DB","slug":"placebo-pla-mtx-db","phase":"phase_3","mechanism":"This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation.","indications":["Rheumatoid arthritis (as part of control arm in Phase 3 trial)"],"catalyst":""},{"name":"Placebo for Ipilimumab","genericName":"Placebo for Ipilimumab","slug":"placebo-for-ipilimumab","phase":"phase_3","mechanism":"This is a placebo for Ipilimumab, meaning it has no active therapeutic effect.","indications":["Metastatic melanoma"],"catalyst":""},{"name":"Placebo for Nivolumab","genericName":"Placebo for Nivolumab","slug":"placebo-for-nivolumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trials of Nivolumab"],"catalyst":""},{"name":"Placebo for apixaban","genericName":"Placebo for apixaban","slug":"placebo-for-apixaban","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in apixaban clinical trials (specific indication depends on parent trial)"],"catalyst":""},{"name":"Placebo matching BMS-790052","genericName":"Placebo matching BMS-790052","slug":"placebo-matching-bms-790052","phase":"phase_3","mechanism":"BMS-790052 is a direct-acting antiviral agent that inhibits hepatitis C virus (HCV) NS5A protein, blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1)"],"catalyst":""},{"name":"Placebo matching Dacarbazine","genericName":"Placebo matching Dacarbazine","slug":"placebo-matching-dacarbazine","phase":"phase_3","mechanism":"This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient.","indications":["Control arm in Phase 3 trial (specific indication unknown without trial protocol)"],"catalyst":""},{"name":"Placebo matching Ipilimumab","genericName":"Placebo matching Ipilimumab","slug":"placebo-matching-ipilimumab","phase":"phase_3","mechanism":"This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator.","indications":["Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens"],"catalyst":""},{"name":"Placebo matching Ribavirin","genericName":"Placebo matching Ribavirin","slug":"placebo-matching-ribavirin","phase":"phase_3","mechanism":"This is a placebo control matching the appearance and dosing schedule of ribavirin, an antiviral nucleoside analog that inhibits viral RNA synthesis.","indications":["Placebo control in phase 3 clinical trials for viral infections (specific indication dependent on trial design)"],"catalyst":""},{"name":"Placebo matching with Abatacept","genericName":"Placebo matching with Abatacept","slug":"placebo-matching-with-abatacept","phase":"marketed","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"Placebo matching with Metformin XR","genericName":"Placebo matching with Metformin XR","slug":"placebo-matching-with-metformin-xr","phase":"marketed","mechanism":"This is a placebo formulation matched to Metformin XR for use as a control in clinical trials, containing no active pharmaceutical ingredient.","indications":["Clinical trial control for studies evaluating Metformin XR efficacy and safety"],"catalyst":""},{"name":"Prenisolone","genericName":"Prenisolone","slug":"prenisolone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"REZIPAS","genericName":"AMINOSALICYLIC ACID RESIN COMPLEX","slug":"aminosalicylic-acid-resin-complex","phase":"marketed","mechanism":"Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","indications":["Acute tuberculosis","Pulmonary tuberculosis"],"catalyst":""},{"name":"Regorafinib","genericName":"Regorafinib","slug":"regorafinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Reyataz","genericName":"ATAZANAVIR","slug":"atazanavir","phase":"marketed","mechanism":"Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Ribasphere","genericName":"Ribasphere","slug":"ribasphere","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ritonavir (heat-stable)","genericName":"Ritonavir (heat-stable)","slug":"ritonavir-heat-stable","phase":"marketed","mechanism":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","indications":["HIV-1 infection (in combination with other antiretroviral agents)","Pharmacokinetic booster for other protease inhibitors"],"catalyst":""},{"name":"SAR302503","genericName":"SAR302503","slug":"sar302503","phase":"phase_3","mechanism":"SAR302503 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"Subcutaneous (SC) abatacept","genericName":"Subcutaneous (SC) abatacept","slug":"subcutaneous-sc-abatacept","phase":"phase_3","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Adult-onset Still's disease"],"catalyst":""},{"name":"Sustiva","genericName":"Sustiva","slug":"sustiva","phase":"marketed","mechanism":"Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Sustiva","genericName":"EFAVIRENZ","slug":"efavirenz","phase":"marketed","mechanism":"Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Thalomid","genericName":"THALIDOMIDE","slug":"thalidomide","phase":"marketed","mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth.","indications":["Newly Diagnosed Multiple Myeloma","Acute Treatment of Moderate to Severe ENL","Maintenance Therapy for ENL Recurrence"],"catalyst":""},{"name":"Treatment A: Mavacamten intact oral capsule","genericName":"Treatment A: Mavacamten intact oral capsule","slug":"treatment-a-mavacamten-intact-oral-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Videx","genericName":"DIDANOSINE","slug":"didanosine","phase":"marketed","mechanism":"Small molecule","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Yervoy","genericName":"Yervoy","slug":"yervoy","phase":"marketed","mechanism":"Cytotoxic T-lymphocyte protein 4","indications":["High grade squamous intraepithelial neoplasia of esophagus","Metastatic malignant melanoma","Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","Microsatellite instability-high colorectal cancer","Renal cell carcinoma"],"catalyst":""},{"name":"abatacept (ABA)","genericName":"abatacept (ABA)","slug":"abatacept-aba","phase":"marketed","mechanism":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","indications":["Rheumatoid arthritis","Polyarticular juvenile idiopathic arthritis","Psoriatic arthritis","Ankylosing spondylitis","Systemic lupus erythematosus"],"catalyst":""},{"name":"or Glyburide alone.","genericName":"or Glyburide alone.","slug":"or-glyburide-alone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"or Metformin HCl alone","genericName":"or Metformin HCl alone","slug":"or-metformin-hcl-alone","phase":"marketed","mechanism":"Metformin HCl reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in patients with type 2 diabetes.","indications":["Type 2 diabetes mellitus","Prediabetes (off-label or prevention studies)","Polycystic ovary syndrome (PCOS) with insulin resistance"],"catalyst":""},{"name":"panHer","genericName":"panHer","slug":"panher","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"stavudine, efavirenz, lamivudine","genericName":"stavudine, efavirenz, lamivudine","slug":"stavudine-efavirenz-lamivudine","phase":"phase_3","mechanism":"This is a fixed-dose combination of three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase.","indications":["HIV-1 infection"],"catalyst":""}],"recentEvents":[{"date":"2022-02-01","type":"regulatory","headline":"FDA Approves Opdivo + Yervoy Combination for First-Line Treatment of Metastatic NSCLC","summary":"The FDA has approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients without EGFR or ALK genomic tumor aberrations.","drugName":"Opdivo + Yervoy","sentiment":"positive"},{"date":"2021-12-01","type":"earnings","headline":"Bristol-Myers Squibb Reports Fourth-Quarter and Full-Year 2021 Results","summary":"BMY reported fourth-quarter and full-year 2021 results, with revenue of $11.6 billion and a net loss of $1.4 billion.","drugName":"","sentiment":"neutral"},{"date":"2021-06-01","type":"deal","headline":"Bristol-Myers Squibb and Biogen Announce Collaboration to Develop and Commercialize Ocrevus in the US","summary":"BMY and Biogen announced a collaboration to develop and commercialize Ocrevus (ocrelizumab) in the US for the treatment of relapsing forms of multiple sclerosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQNEZxZlZBT25yRkItX05hcFc0am0tem1VbmhwVlpOcWJaYlFxLWs1bUVKc1hnLUh4dkFhejdkNW5xM011RkZpa0NRdEx4aE03ZWFRcnk3aFBHbmNrQlRUSUhHVWluTjZoS09sSXhNdGhwVkhhQkJHbUFISXdoQnFBRklfWkhJV2k2TXdlbmIzU0NPcG8tZWxxZmpLVC1ESWN6dGp0eUlnTzFuQ0lzYkNjWUMtcGlIUi1hTWc?oc=5","date":"2026-04-08","type":"pipeline","source":"AD HOC NEWS","summary":"Bristol-Myers Squibb Company stock: What you should know now - AD HOC NEWS","headline":"Bristol-Myers Squibb Company stock: What you should know now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPWmR1RlE4MlM3bjhwejhVZUNEdUtNbzZndXZUYXlQRmR6eEpwbWFWTTM3NWlVS0N5UmFaOUtPYUNQWHhhaXYxWXNaNWNxMFh4OTE5aUFfVkg0QVpYc1oyWnZvTkx1U3lwb1F4QTdvRGR6UFJWNHJNS2JQU2F4MHJiNlI4YlRpbHZ2amFiMWVlNWdjVDN1Y2lvZ0QtT0xOM0xUSnRCc1JLaHlGSlBzVzBValZXN0pOS2I1ZmhTUDRCcU9KU3N2clZtd3BIbl93MUpNaU1XMDJfTGIxU3lXZ3pQak5QNHBYS2I4TldRbnpJTUF4WFM1SDI5NzNaazVLdzMtQWhOYWRnWkRSV3I4TFE?oc=5","date":"2026-04-07","type":"pipeline","source":"The Corner .eu","summary":"Rovi completes acquisition of pharmaceutical manufacturing plant in Phoenix, Arizona, following execution of agreement with Bristol Myers Squibb - The Corner .eu","headline":"Rovi completes acquisition of pharmaceutical manufacturing plant in Phoenix, Arizona, following execution of agreement w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQVlZmM3hKUVRqX2duZFJna2RmWkdpUzVFZjNHZWplMnRHVVVqSHE5NG1vUldNaEx2ZjhoOW13cWtNWkg5NkJ6Y0ptVTMzeTc1eDBkWHUwTHpseVRVSDI3T0xXeFNhS1ktX2RlMmphZVJiNXQ5aF9zQnV0Y29kdHNJWUdQdnFDWVJmSXFSZ1p5ZXBRRmJTTHBfaE9vX0k4a0RadjBDZzNSeFRZSEpwYTNNc1lWRzFudlg1NWFKbEFQaW5ZY3YyYmFnRGg0RXJFMjVrR2prSmt0MU1PeVZxYW5uUTZLa2ZKT3QyQ3dRLUs2Vm5qRzFmeXVhT1JWejBmeERaQkFsQ21ub1FEM0FHeEotc2dEbk14U2d2ZWlOOGg4RTRVRS1pLVZDLU54YlR0TVkxTTdJZVpqWDNqSDlvY3UtY2s0R1A4eFlj?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Bar","headline":"Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks - simplywall.st","headline":"A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQZkJwM0VrdHp3UEpMLWhVTTdsczUyNFhTano2VTB2R3VJcjhxa1p5N19DaFdvMGRieTRCQ0diTFVGMm1iMlp5empQUlJNWXREdTZPLWhnaUliQXRac2NJZllieUZqd21ESi00QUstVmhzM0t6RnNZSE5QVnhuS04ycjVYZEVJVE1NY1lFMmJwVkw2VFBPR19ad3QxaEpyLVhYTmtjeDZRSWw?oc=5","date":"2026-04-03","type":"deal","source":"The Business Journals","summary":"Spanish pharma firm enters Phoenix market after deal with Bristol Myers Squibb - The Business Journals","headline":"Spanish pharma firm enters Phoenix market after deal with Bristol Myers Squibb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQQ09QRFNDMHkxYlo3NkZBaVN5Z0p1QjhIb0V0WF9PNUtpRjZKXzFONnpiME9za19IeXN4b0ZYN0hfNGhpbFY2T3pOZzhhYXhhNkVHbDBQM2gyelZ3TG1sTGhCdHVPb0pMc08zQ2cyZXFnTGhCQThMR09fcUFNQ3RaMTVoSkNLLWt6LXRVTUEySmZZNENVMjZYQnF6NkxYZ1dneTd6Tkg1bGV2Zjg?oc=5","date":"2026-04-03","type":"pipeline","source":"Yahoo Finance","summary":"AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance","headline":"AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNRVNVU2FSQ0lHSkQ5eVBDbDhYaU80bmZDOE5FSDRwRGpKaDU4elg3S3ZRNTJJX1FKTTQwa21yYXVxME9NVl9pMDdNQjJNVlVGT1l5VFBTTTFpWWFSdllNbkw0VU1QS0lnU1VoVjJrb0NGamhrWlpZMkRxLUVZTThaSmhoNV92VFpmZzh3MHBVY3EtV25q?oc=5","date":"2026-03-31","type":"trial","source":"Fierce Biotech","summary":"BMS links up with Faro to use AI to improve clinical trial protocols - Fierce Biotech","headline":"BMS links up with Faro to use AI to improve clinical trial protocols","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE05eFpyQm54ZExiQXJQbXdEeTJ2UndoZFZqV21samVvOW1POVNfa1E3bnhvWW9zWjVIQUZVZEVLRmg5cE56dEZKcURyZHotbGsxV19kUkZBRFdoblNBU2FjTzA0TVZQb1R1czNycVN6d1NMdw?oc=5","date":"2026-03-17","type":"patent","source":"Labiotech.eu","summary":"Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff? - Labiotech.eu","headline":"Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNMmlVSVBuRkxFdXVWQW56YUJaUDhLbjZtWTVmSDNYcjVpUWh2bHY0cWY0bU45UmtXX1dFa0h4cjRHLXZSd0czSjJxWndHOFRpbVlkZG9sQ3BYU3RaVXpFMjk1Z1ljUlNUTmsyQnByS2VsNDhfYmtSOTBXZUlsNkM1RDJDV20yMkJOT3NNWERmUVZpRkNtbWFpRnVDaVc?oc=5","date":"2026-02-02","type":"pipeline","source":"statnews.com","summary":"Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s - statnews.com","headline":"Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQLUQ3Qm1UaDNMM2FiaEdtanFTdWZDOXhkdk9WMENXMkZySHUwWnB6YUU1Q191QjhkSzJwQl9UZmh5bnZISHdaLTRZQzJWT1ZOX0tocThwZl9Bd2ROcFJKb1cyT3BZMjFsSjU2RWt1aUY0U1lfVTl3Z3lFOVhQZ3N3c3JEdjJLcXBiMjVHZGdPRjdpMVFKV2h0NElpOVBnRnZkeGxEYW42NFRlR1NvM1M2cWkwVTI3S3hqc2prNjdRaXk2bEt5d1g2ZHczUnFKN3ZNcEZyaDd5bUU?oc=5","date":"2026-01-20","type":"deal","source":"Reuters","summary":"Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters","headline":"Bristol Myers partners with Microsoft for AI-driven lung cancer detection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPeDBobm0zTjI0MFZ6aUN3Y0JlR29qWG04TzdFZUtac1hMaHNSNkVmQVQ4OXpUcTFfZFR1VHFtOFc0blVSMUVFdEtDQUFDZXpUdE1BeWY0TENyVEhta3VmclVyc0w1d1FwanpudktuLVdxc244bmo1R2c1N1lRMDU3Z0dGcjhqTWtwNncxSEI4UGlKY2pyaVhCNGdOSk9DVEZsUjlUY3ZR?oc=5","date":"2025-11-14","type":"pipeline","source":"Bristol Myers Squibb","summary":"Veterans redefining manufacturing leadership in pharma - Bristol Myers Squibb","headline":"Veterans redefining manufacturing leadership in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWF9oRU9sOWFGcTNfWGFqNHNPaEFvalhjbnhqWURVb3hEbnVFblVoSENoMmthbVlBbHA3NHc2NlZaQVlXVDlCOWhFSDFCSFlmWkxZaEYzVTBRamxpaUVsSXhxalhPMU5XVkxlUk11UV9TWEpIdWVqQU5sTHJVTWFlNWhua1FIay14OUZrSEctYTloN3RxRDMtcG00ODM1WDVoMGlPNWpyY2pqa3lrUFE?oc=5","date":"2025-09-15","type":"pipeline","source":"Fierce Pharma","summary":"BMS sells controlling stake in historic US-China pharmaceutical joint venture - Fierce Pharma","headline":"BMS sells controlling stake in historic US-China pharmaceutical joint venture","sentiment":"neutral"}],"patents":[{"drugName":"Yervoy","drugSlug":"ipilimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8148356","type":"Formulation","expiryDate":"2026-05-21","territory":"US","genericFilings":[]},{"drugName":"Orencia","drugSlug":"abatacept","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"12053482","type":"Method of Use","expiryDate":"2029-05-14","territory":"US","genericFilings":[]},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"11571436","type":"Formulation","expiryDate":"2029-05-14","territory":"US","genericFilings":[]},{"drugName":"Vidaza","drugSlug":"azacitidine","patentNumber":"8846628","type":"Formulation","expiryDate":"2030-06-03","territory":"US","genericFilings":[]},{"drugName":"Eliquis","drugSlug":"apixaban","patentNumber":"9326945","type":"Formulation","expiryDate":"2031-02-24","territory":"US","annualRevenue":14443000000,"genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9327028","type":"Method of Use","expiryDate":"2031-07-21","territory":"US","genericFilings":[]},{"drugName":"Eliquis","drugSlug":"apixaban","patentNumber":"9326945*PED","type":"Compound","expiryDate":"2031-08-24","territory":"US","annualRevenue":14443000000,"genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8722738","type":"Method of Use","expiryDate":"2032-04-06","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"8747894","type":"Formulation","expiryDate":"2032-05-08","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9561204","type":"Method of Use","expiryDate":"2032-05-08","territory":"US","genericFilings":[]},{"drugName":"Acetadote","drugSlug":"acetylcysteine","patentNumber":"9427421","type":"Formulation","expiryDate":"2032-05-08","territory":"US","genericFilings":[]}],"drugCount":184,"phaseCounts":{"marketed":78,"discontinued":2,"phase_2":36,"phase_3":54,"phase_1":14},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co.","Eli Lilly and Company","Pfizer Inc."],"therapeuticFocus":["Oncology","Immunology","Cardiovascular Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":48194000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":48194000000,"period":"2025-12-31"},{"value":48300000000,"period":"2024-12-31"},{"value":45006000000,"period":"2023-12-31"},{"value":46159000000,"period":"2022-12-31"},{"value":46385000000,"period":"2021-12-31"},{"value":42518000000,"period":"2020-12-31"}],"grossProfit":30745000000,"grossProfitHistory":[{"period":"2025-12-31","value":34259000000},{"period":"2024-12-31","value":34332000000},{"period":"2023-12-31","value":34313000000},{"period":"2022-12-31","value":36022000000}],"rdSpend":9951000000,"rdSpendHistory":[{"period":"2025-12-31","value":9951000000},{"period":"2024-12-31","value":11159000000},{"period":"2023-12-31","value":9299000000},{"period":"2022-12-31","value":9509000000}],"sgaSpend":7267000000,"operatingIncome":13724000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":13724000000},{"period":"2024-12-31","value":5887000000},{"period":"2023-12-31","value":8195000000},{"period":"2022-12-31","value":9104000000}],"netIncome":7054000000,"netIncomeHistory":[{"period":"2025-12-31","value":7054000000},{"period":"2024-12-31","value":-8948000000},{"period":"2023-12-31","value":8025000000},{"period":"2022-12-31","value":6327000000}],"eps":3.46,"epsHistory":[{"period":"2025-12-31","value":3.46},{"period":"2024-12-31","value":-4.41},{"period":"2023-12-31","value":3.86},{"period":"2022-12-31","value":2.95}],"cash":10209000000,"cashHistory":[{"period":"2025-12-31","value":10209000000},{"period":"2024-12-31","value":10346000000},{"period":"2023-12-31","value":11464000000},{"period":"2022-12-31","value":9123000000}],"totalAssets":90038000000,"totalLiabilities":71532000000,"totalDebt":47139000000,"equity":18473000000,"operatingCashflow":14156000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":14156000000},{"period":"2024-12-31","value":15190000000},{"period":"2023-12-31","value":13860000000},{"period":"2022-12-31","value":13066000000}],"capex":-1311000000,"capexHistory":[{"period":"2025-12-31","value":-1311000000},{"period":"2024-12-31","value":-1248000000},{"period":"2023-12-31","value":-1209000000},{"period":"2022-12-31","value":-1118000000}],"freeCashflow":12845000000,"dividendsPaid":-5045000000,"buybacks":0,"employees":32500,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1617000000,"ebit":3651000000,"ebitda":4245000000,"period":"2026-03-31","revenue":11489000000,"epsBasic":1.31,"netIncome":2677000000,"rdExpense":2649000000,"epsDiluted":1.31,"grossProfit":8068000000,"operatingIncome":3365000000},{"sga":2181000000,"ebit":1902000000,"ebitda":2879000000,"period":"2025-12-31","revenue":12503000000,"epsBasic":0.53,"netIncome":1087000000,"rdExpense":2586000000,"epsDiluted":0.53,"grossProfit":8406000000,"operatingIncome":2813000000},{"sga":1789000000,"ebit":3594000000,"ebitda":4605000000,"period":"2025-09-30","revenue":12222000000,"epsBasic":1.08,"netIncome":2201000000,"rdExpense":2528000000,"epsDiluted":1.08,"grossProfit":8787000000,"operatingIncome":3639000000},{"sga":1713000000,"ebit":2258000000,"ebitda":3269000000,"period":"2025-06-30","revenue":12269000000,"epsBasic":0.64,"netIncome":1310000000,"rdExpense":2580000000,"epsDiluted":0.64,"grossProfit":8897000000,"operatingIncome":3774000000},{"sga":1584000000,"ebit":3465000000,"ebitda":4477000000,"period":"2025-03-31","revenue":11201000000,"epsBasic":1.21,"netIncome":2456000000,"rdExpense":2257000000,"epsDiluted":1.2,"grossProfit":8168000000,"operatingIncome":3497000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":56.65,"previousClose":56.39,"fiftyTwoWeekHigh":62.89,"fiftyTwoWeekLow":42.52,"fiftyTwoWeekRange":"42.52 - 62.89","fiftyDayAverage":58.73,"twoHundredDayAverage":52.34,"beta":0.26,"enterpriseValue":151129391104,"forwardPE":9.2,"priceToBook":5.76,"priceToSales":2.39,"enterpriseToRevenue":3.12,"enterpriseToEbitda":7.96,"pegRatio":178,"ebitda":18973999104,"ebitdaMargin":39.1,"freeCashflow":9851750400,"operatingCashflow":13306000384,"totalDebt":46428999680,"debtToEquity":231,"currentRatio":1.42,"returnOnAssets":10.7,"returnOnEquity":38.7,"analystRating":"2.5 - Hold","recommendationKey":"hold","numberOfAnalysts":25,"targetMeanPrice":62.96,"targetHighPrice":75,"targetLowPrice":40,"dividendRate":2.52,"payoutRatio":0.7,"fiveYearAvgDividendYield":3.93,"exDividendDate":1775088000,"insiderHeldPercent":0.1,"institutionHeldPercent":84.3,"sharesOutstanding":2042071247,"floatShares":2038885616,"sharesShort":31330595,"shortRatio":3.08,"shortPercentOfFloat":1.5,"epsTrailing":3.57,"epsForward":6.15,"revenuePerShare":23.82,"bookValue":9.83,"officers":[{"age":54,"name":"Dr. Christopher S. Boerner Ph.D.","title":"CEO & Chairman"},{"age":57,"name":"Mr. David V. Elkins","title":"Executive VP & CFO"},{"age":52,"name":"Mr. Greg  Meyers","title":"Executive VP and Chief Digital & Technology Officer"},{"age":53,"name":"Mr. Adam  Lenkowsky","title":"Executive VP & Chief Commercialization Officer"},{"age":56,"name":"Mr. Cristian  Massacesi M.D.","title":"Executive VP, Chief Medical Officer & Head of Development"},{"age":60,"name":"Ms. Karin  Shanahan","title":"Executive VP, Chief Supply Chain & Operations Officer"},{"age":null,"name":"Mr. Charles E. Triano","title":"SVP & Head of Investor Relations"},{"age":45,"name":"Ms. Cari  Gallman","title":"Executive VP, General Counsel & Chief Policy Officer"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.bms.com/investors/Pages/home.aspx","website":"https://www.bms.com","phone":"609 252 4621"}}